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Pancreatic cancer is a highlyaggressive andnotoriouslydiﬃcult to treat. As the vastmajorityofpatients are diagnosedat advanced
stageofthedisease,onlyasmallpopulationiscurativebysurgicalresection.Althoughgemcitabine-basedchemotherapyistypically
oﬀered as standard of care, most patients do not survive longer than 6 months. Thus, new therapeutic approaches are needed.
Pancreatic cancer cells that develop gemcitabine resistance would still be suitable targets for immunotherapy. Therefore, one
promising treatment approach may be immunotherapy that is designed to target pancreatic-cancer-associated antigens. In this
paper, we detail recent work in immunotherapy and the advances in concept of combination therapy of immunotherapy and
chemotherapy. We oﬀer our perspective on how to increase the clinical eﬃcacy of immunotherapies for pancreatic cancer.
1.PancreaticCancer
Pancreatic tumors usually display a ductal, an acinar, or
an endocrine diﬀerentiation. The majority (approximately
95%) of pancreatic tumors aris ef r o mt h ee x o c r i n ec o m -
ponent of the pancreas, and of these the signiﬁcantly most
common is ductal adenocarcinoma [1]. Pancreatic adeno-
carcinoma that is the ﬁfth leading cause of cancer death
worldwide isalethaldiseasewith anoverall5-year survivalof
only 6% [1]. Moreover, for locally advanced cancer patients,
the life expectancy is about 6-8 months [1]. No adequate
therapy for pancreatic cancer has yet been found, and most
of patientsdiagnosed annually die within a year ofdiagnosis.
Despite recent improvements in diagnostic techniques,
pancreatic cancer is diagnosed at an advanced stage in most
patients. Therefore, surgical resection (pancreaticoduo-
denectomy) can be performed in only a small number of
patients [2]. Even after resection, recurrence occurs in the
majority of the patients, leading to a median survival of
about 18 months after resection. Although adjuvant treat-
ment with both chemotherapy and radiation therapy was
investigated, which demonstrated improvements in disease-
free survival and overall survival rates [3], new therapeutic
approaches are still needed.
2. CytotoxicChemotherapeuticAgents
Gemcitabine (2 2 -diﬂuorodeoxycytidine) is a chemother-
apeutic drug that has become the standard treatment for
advanced disease after showing superiority over5-ﬂuoroura-
cil (5-FU), while chemoradiation plus systemic chemother-
apy is also still widely used [4]. Therefore, gemcitabine was
established as the standard ﬁrst line treatment for patients
with advanced disease. Gemcitabine is a nucleoside analogue
that exerts its antitumor activity via multiple mechanisms
of action. These include (1) incorporation of gemcitabine
into replicating DNA, which inhibits DNA replication and2 Clinical and Developmental Immunology
cell growth, (2) masked DNA chain termination, and (3)
several self-potentiation mechanisms that serve to increase
intracellular levels of the active compound [5]. It thus halts
DNA synthesis and is invisible to DNA repair systems,
leading the cells into the apoptotic pathway. However, most
patients treated with gemcitabine do not survive longer
than 6 months, as the tumor cells are naturally resistant to
currentchemotherapy.Subsequenttrials aimedat improving
survival have combined gemcitabine with various cytotoxic
(platinums, ﬂuoropyrimidines, or topoisomerase inhibitors)
[6–10], or biological agents (tipifarnib [11], marimastat
[12], or cetuximab [13]). However, the addition of the
cytotoxic agents to gemcitabine did not lead to a statistically
signiﬁcant improvement in overall survival (OS) in patients
with advanced pancreatic cancer [14–17].
3.Biological Agents
Some therapies based on mechanisms that target speciﬁc
biologicpathwaysoftumorshavecommonlybeenreferred to
as “targeted therapy.” While traditional cytotoxic drugs also
targetspeciﬁccellularprocess,thenewergenerationofagents
is set apart by their targeting of a pathway or molecular
that derives the growth, speed, survival, or maintenance
of tumor cells specially. There is a sound rationale for
combining a human epidermal growth factor receptortype 1
(HER1/EGFR) inhibitor and gemcitabine in pancreatic can-
cer. Erlotinib (Taraceva, Genentech, South San Francisco) is
a small molecule HER1/EGFR tyrosine kinase inhibitor. The
human HER1/EGFR is overexpressed in many pancreatic
tumors and is associated with more aggressive disease and
poorer outcome [18, 19]. Blocking HER1/EGFR tyrosine
kinase signaling improves the anticancer eﬀects of gemc-
itabine [20]. Indeed, the combination of gemcitabine plus
erlotinib signiﬁcantly improved OS compared with gemc-
itabine alone [17]. This combination therapy ﬁrst provided
proof of principle of targeting HER1/EGFR in pancreatic
c a n c e ra n ds h o w e de r l o t i n i b - i m p r o v e ds u r v i v a lw h e nu s e d
concurrently with gemcitabine. Therefore, the US Food and
Drug Administration (FDA) recently approved erlotinib for
use in the ﬁrst-line setting of advanced pancreatic cancer in
combination with gemcitabine. However, this survival bene-
ﬁtwassmall,andthecombinationtherapyincreasedthecost;
therefore, erlotinib has not yet been widely incorporated
into standard treatment protocols. Another study evaluating
EGFR as a target in pancreatic cancer, using the monoclonal
antibody cetuximab, has been completed. In patients with
advanced pancreas cancer, cetuximab did not improve the
outcome compared with patients treated with gemcitabine
alone [13]. Moreover, studies evaluating monoclonal anti-
bodies to vascular endothelial growth factor (VEGF) and
using combinations of targeted agents in patients with ad-
vanced pancreatic cancer are underway.
4.Immunotherapy
The aim of antitumor immunotherapy is to induce eﬃcient
cytotoxic T lymphocyte (CTL) responses against pancreatic
cancer cell. Dendritic cells (DCs) are powerful antigen-pre-
senting cells (APCs) that play a pivotal role in the initiation,
programming, and regulation of tumor-speciﬁc immune
responses [21, 22]. DCs can process endogenously synthe-
sized antigens or exogenous antigens into antigenic pep-
tides, presented to the cell surface as MHC class I-peptide
complexes, and recognized by the αβ T cell receptor (TCR)
in CD8+ T cells [23]. In contrast, exogenous antigens are
captured and delivered to the compartments of the endo-
some/lysosome, where they are degraded to antigenic pep-
tides by proteases and peptidases, which are complexed with
MHC class II and recognized by the αβ TCR in CD4+ T cells
[23–25].Theαβ TCRinCD8+CTLcanrecognizeMHCclass
I-peptide complexes on cancer cells and destroy cancer cells
through eﬀector molecules such as granzyme B and perforin
(Figure 1)[ 26, 27]. Upon TCR-mediated cell activation,
naive CD4+ T cells can diﬀerentiate into at least four major
lineages, Th1, Th2, Th17, and regulatory T (Treg) cells all
of which participate in diﬀerent types of immune responses
(Figure 2)[ 28]. The Th1 cells produce interferon (IFN)-
γ along with proinﬂammatory cytokines, such as tumor
necrosis factor (TNF)-α and TNF-β,t oa c t i v a t eD C s ,w h i c h
can regulate the survival and persistence of CD8+ CTLs as
memory cells [24, 29]. Th2 cells secrete interleukin (IL)-4
and IL-10 [24, 29]. The Th2 response is often associated
with the humoral, antibody-based antitumor response [30,
31]. Th17 cells secrete IL-17 and IL-22, eliciting tissue
inﬂammation implicated in autoimmunity [32–34]. There
are increasing evidences that cancer cells-derived soluble
factors promote the induction of tolerance through the
generationof CD4+ α chain of IL-2R (CD25)+forkhead box
P3 (Foxp3)+ Treg subset, which is linked to compromised
antitumor immune responses [35].
The ﬁeld of cancer immunotherapy is currently in an
active state of preclinical and clinical investigations. The de-
velopment of new treatment modalities, including speciﬁc
immunotherapy, is of great importance in the treatment
of pancreatic cancer. In support of the immunotherapy
approach are the ﬁndings that pancreatic cancer cells express
T A A ss u c ha sW i l m s ’t u m o rg e n e1( W T 1 )( 7 5 % )[ 36],
mucin 1 (MUC1) (over 85%) [37], human telomerase
reverse transcriptase (hTERT) (88%) [38], mutated K-RAS
(73%) [38, 39], survivin (77%) [40], carcinoembryonic
antigen (CEA) (over 90%) [41], HER-2/neu (61.2%) [42],
or p53 (67%) [43] as potential targets for immunotherapy.
Immunotherapies aim to recruit and activate T cellsthat rec-
ognize TAAs-speciﬁc antigens. Moreover, pancreatic cancer
cells themselves actively contribute to immune suppression
through production of immune suppressive cytokines (e.g.,
TGF-β, IL-10, and IL-6) and by expressing surface molecules
that mediate immune suppression (e.g., vascular endothelial
growth factor (VEGF), Fas ligand (Fas-L), programmed
death-1 ligand (PD-L1) and indolamine-2, and 3-dioxygen-
ase (IDO)) [44]. In addition, the environment in pancreatic
cancer is consisted of not only cancer cells but also immune
suppressive cells such as cancer-associated ﬁbroblasts
(CAFs), tolerogenic DCs, myeloid-derived suppressor cells
(MDSCs), immunosuppressive tumor-associated macro-
phages (TAMs), and Treg cells [44]( Figure 3). As a result,Clinical and Developmental Immunology 3
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Figure 1: CTL induction by DCs. Antigens are takenup and degraded into peptide fragments by antigen-presenting cells, such as immature
DCs. DCs process tumor-derived peptides and MHC class I peptides derived from DCs. They form MHC class I-peptide complexes, in
the endoplasmic reticulum, which are transported to the surface of DCs and presented to CD8+ T cells. DCs also synthesize MHC class II
peptides in the endoplasmic reticulum, which are transported to the cytoplasm where MHC class II-peptide complexes are assembled with
tumor-derived peptides and presented to CD4+ T cells. The CD4+ T cells produce increased amounts of IL-2, which drives CD8+ T-cell
proliferation. CD8+ T cells then become CTL, which can destroy cancer cells through eﬀector molecules such as granzyme B and perforin.
immunosuppressive cells inhibit antitumor immunity by
various mechanisms, including depletion of arginine and
elaboration of reactive oxygen species (ROS) and nitrogen
oxide (NO) [44]. Finally, an immunosuppressive tumor
microenvironment induced by pancreatic cancers suppresses
CD8+ CTL function through secretion of IL-10 and TGF-β
from Treg cells [45, 46]. The accumulation of these immune
suppressive cellsin pancreatic cancermight be closelyrelated
to the extent ofdisease and correlated well with disease stage.
Therefore, immunotherapies that struggle against pancreatic
cancercellswith antigen-speciﬁc CTLsas well asdepletionof
Tregcellsmaytipthebalanceinfavorofimmunostimulation.
Currently, the ﬁeld of cancer immunotherapy using peptide-
or cell- (DC or whole tumor cell)-based approaches is in an
active state of preclinical and clinical investigations.
5.PeptideVaccines
TCR engagement by peptide/MHC constitutes the main sig-
nal for the activation of naive CD4+ and CD8+ T cells. Al-
though CD8+ naive T cells recognize peptides derived from
TAAs bound by MHC class I molecules, it is not suﬃcient
to initiate a productive generation of antigen-speciﬁc CTLs.
Full induction of CTLs requires additional signals driven
by costimulatory molecules on DCs. CD8+ CTLs can
respond to TAAs-derived peptides presented in the context
of MHC class I molecules on tumor cells. Therefore, many
investigators have tried to identify MHC class I-binding
peptides that could be utilized to developtumor vaccines for
treatment of cancer patients. Peptide-based cancer vaccines
are preparations made from antigenic protein fragments
(called epitopes) that represent the minimal immunogenic
region of antigens [47, 48]. The increased understanding
of antigen recognition at molecular level has resulted in
the development of rationally designed peptide vaccines.
Indeed, the peptide-based cancer vaccines for pancreatic
cancer have undergone phase I/II clinical trials [49, 50].
The major advantages of peptide vaccines are that they are
simple, safe, stable, and economical. Induction of CTLs need
peptides derived from TAAs to be presented on the surface
of APCs such as DCs in the context of HLA molecules.
However, several obstacleslimit the widespread usefulness of
peptide vaccines. The drawback of this strategy comes from
numerousfactors:(i)alimitednumberofknownsynthesized4 Clinical and Developmental Immunology
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Figure 2: Immune homeostasis.Upon TCR-mediated cell activation, naive CD4 T cells can diﬀerentiate into four majorlineages, Th1, Th2,
Th17,and Treg cells thatparticipate indiﬀerent types of immune responses. The Th1 cells produce IFN-γ andIL-2, resulting ininduction of
CD8+ CTLs. Th2 cells secrete IL-4 and IL-10. The Th2 response is associated with the humoral, antibody-based antitumor response. Th17
cells secrete IL-17 and IL-22, eliciting tissue inﬂammation implicated in autoimmunity. Treg cells that secrete TGF-β and IL-10 suppress
eﬀector Th1 or Th2 cells.
short peptides cannot be available in many HLA molecules
[51–53], (ii) CD8+ CTLs may be ineﬀective in reacting with
pancreatic cancer cells downregulated by certain tumor anti-
gens and MHC class I molecules, which may appear during
the course oftumor progression [22], (iii)impaired function
ofAPCsinpatientswithadvancedpancreaticcancer[54,55],
and (iv) MDSCsor Treg cellsin tumor environment produce
immunosuppressive cytokinessuch asIL-10and TGF-β[26].
Vaccination with synthetic peptides, particularly MHC
class I-binding epitopes, has been performed in pancreatic
cancer (Table 1). In a phase I/II trials, vaccination for the
patients with advanced pancreatic cancer using mutant K-
ras [39, 56, 57], MUC1 [58, 59], or telomerase [60]p e p t i d e s
wassigniﬁcantlyassociatedwithimmuneresponses.Gjertsen
et al. [56] ﬁrst reported mutant K-ras peptide vaccines for
pancreatic cancer. Since native epitopes have relatively low
immunogenicity, granulocyte-macrophage colony-stimulat-
ingfactor(GM-CSF)wasappliedtoachieveeﬃcientvaccina-
tion in the study. Among 48 patients with pancreatic cancer
(10 surgically resected and 38 with advanced disease), vacci-
nation of mutant K-ras peptides in combination with GM-
CSF resulted in immune responses and prolonged survival.
Moreover, another group also reported that vaccination of
24 patients with resected pancreatic cancer with K-ras
peptide in combination with GM-CSF proved to be safe
withouttumorregression [57]. InanMUC1peptidevaccine,
vaccination of 16 patients with resected or locally advanced
pancreatic cancer with 100 mer MUC1 peptide and SB-
AS2 adjuvant resulted in low but detectable MUC1-speciﬁc
immune responses in some patients [59].Moreover, vaccina-
tion with 100 mer MUC1 peptide and incomplete Freund’s
adjuvant resulted in increased circulating anti-MUC1 IgG
antibody in some patients [58]. In addition, augmented
immune responses and prolonged survival were observed
following vaccination ofadvanced pancreatic cancer patients
with telomerase peptide and GM-CSF [60]. Recent pro-
tocols using personalized peptides demonstrated frequent
induction of tumor reactive T cells [61]. In this regimen,
prevaccinationperipheralbloodmononuclearcells(PBMCs)
were screened for their reactivity in vitro to each peptide in
patients, and only the reactive peptides were vaccinated to
11 patients with advanced pancreatic cancer. In the person-
alized peptide vaccines, augmented immune responses to at
least one of peptides used for vaccination were observed inClinical and Developmental Immunology 5
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Figure 3: Pancreatic cancers induce an immunosuppressive tumor microenvironment. Pancreatic cancer cells secrete various immuno-
suppressive factors such as VEGF, IL-6, IL-10, TGF-β, Fas-L, IDO, PD-L1, and microvesicles, all of which promote the accumulation of
TAM, MDSC, or tolerogenic DC. These immunosuppressive cells inhibit antitumor immunity by various mechanisms, including depletion
of arginine and elaboration of ROS and NO. An immunosuppressive tumor microenvironment induced by pancreatic cancers suppresses
CD8+CTLfunctionthroughsecretion ofIL-10andTGF-β fromTregcells.Allcontributetopancreaticcancer-induced immunesuppression.
the postvaccination PBMCs [62]. In these all peptide vac-
cines, only a limited success has occurred in clinical trials.
The short peptide can be loaded exogenously in MHC
class I molecules and presented by DCs within a few days
after injection to the patients. Moreover, the short peptide
vaccines are not immunogenic enough. The more attractive
peptide-based vaccines may be synthetic long peptides to
induce antigen-speciﬁc polyclonal CD4+ and CD8+ T cells
[63]. As long synthetic peptides are not able to bind directly
on MHC class I or II molecules on DCs, they need to
be taken up, processed, and presented by DCs. The long
peptide vaccines can present MHC class I- and II-restricted
epitopes long time, thus eliciting both CD4- and CD8-
mediated immune recognition [64]. Peptide vaccines aimed
at the treatment of established cancer may require long-lived
presentation of epitopes by MHC class I and II molecules on
appropriately activated DCs. Such presentation is essential
for induction of robust therapeutic T-cell responses.
In a phase I study using long synthetic mutant ras pep-
tides, Weden et al. [65] treated 23 patients who were vac-
cinated after surgical resection for pancreatic cancer. Long-
term immunological memory responses to the vaccines were
observed. Strikingly, 10-year survival was 20% (four patients
outof20 evaluable)versuszero (0/87)in a cohort ofnonvac-
cinated patient treated in the same period. Cancer vaccines
for pancreatic cancer may be tested to prevent recurrence
and metastasis after surgical resection. Furthermore, peptide
vaccines to boost immune responses in combination with
chemotherapy to overcome robust cancers may be the key
elementsfor the developmentof therapeuticcancervaccines.
Indeed, Wobser et al. [40] reported a case of complete re-
mission (CR) of liver metastasis of pancreatic cancer refrac-
tory to gemcitabine chemotherapy under vaccination with a
survivin peptide.
6.Whole TumorCellVaccines
Despite the identiﬁcation of peptides, autologous whole tu-
mor cells remain a potent vehicle for generating antitumor
immunity. This is because tumor cells express all relevant
candidate TAAs, including both known and unidentiﬁed. In
the clinical setting, an autologous whole tumor cell vaccine
depends on the availability of adequate numbers of tumor
cells.Asonly10–15%ofpancreaticcancerpatientsdiagnosed
are eligible for surgical, autologous pancreatic cancer cells
may not be provided in most of the patients. Moreover,
even if the patients are treated by surgical resection, it is
diﬃcult to prepare suﬃcient numbers of tumor cells due to
the length of culture time and potential contamination of
bacteria and fungus [55, 66]. To circumvent this problem,6 Clinical and Developmental Immunology
Table 1: Peptide vaccines.
Patients Peptide vaccine Adjuvant Response Ref.
10 resected and 38
advanced
pancreatic caner
Mutant K-ras peptide GM-CSF
Immune response to the peptide vaccine
showed prolonged survival compared to
nonresponders. [56]
K-ras-speciﬁc T cells were selectively
accumulated in the tumor.
24 resected
pancreatic cancer Mutant K-ras peptide GM-CSF No elicitable immunogenicity and unproven
eﬃcacy was observed.
[57]
16 resected or
locally advanced
pancreatic cancer
100 mer MUC1 peptide SB-AS2 adjuvant Detectable MUC1-speciﬁc humoral and T-cell
responses were detected in some patients.
[59]
6a d v a n c e d
pancreatic cancer 100 mer MUC1 peptide Incomplete Freund’s
adjuvant
One patient showed a tendency for increased
circulating anti-MUC1 IgG antibody.
[58]
48 advanced
pancreatic cancer Telomerase peptide GM-CSF
Immune responses were observed in 24 of 38
evaluable patients. [60]
One-year survival for the evaluable patients in
t h ei n t e r m e d i a t ed o s eg r o u pw a s2 5 % .
11 advanced
pancreatic cance
Personalized peptide
vaccine
The 6- and 12-month survival rates for
patients who received >3v a c c i n a t i o n s( n = 10)
were 80% and 20%, respectively.
[62]
23 resected
pancreatic cancer Mutant ras long peptide
Seventeen of 20 evaluable patients (85%)
responded immunologicallyto the vaccine. [65]
Ten-year survival was 20% (four patients out of
20 evaluable).
1l i v e rm e t a s t a s i so f
pancreatic cancer
refractory to
gemcitabine
Survivin peptide
The patient initially underwent partial
remission of liver metastasis which proceeded
after 6 months into a complete remission with
ad u r a t i o no f8m o n t h s .
[40]
allogeneictumorcell lines may be used instead ofautologous
tumor cells [66] .T h i ss t r a t e g yh a sn u m e r o u sa d v a n t a g e s :
(i) allogeneic tumor cell lines are well characterized as TAA
source, (ii) speciﬁc TAAs do not need to be identiﬁed for
vaccination, (iii) allogeneic tumor cell lines, which shared
with TAAs, can grow well in vitro; thus, there is no limiting
factor for preparation of tumor cells, (iv) it is not necessary
to determine HLA typing of patients and allogeneic tumor
cells, because autologous DCs can process and present
multiple TAAs from allogeneic tumor cells owing to cross-
presentation in the context of appropriate MHC class I
and II alleles, and (v) polyclonal antigen-speciﬁc CD4+
and CD8+ T cells can be generated, which may protect
against tumor escape variants. While currently explored
allogeneic approaches in whole tumor cell-based vaccination
procedures represent an improvement in terms of standard-
ization over their autologous counterparts, they nevertheless
entail the culture of large batches of cells under good
m a n u f a c t u r i n gp r a c t i c e( G M P )g r a d ec o n d i t i o n s .O n eo f
major challenges to develop an allogeneic tumor cell-based
vaccine strategy is to overcome the potential hazards of fetal
calf serum (FCS) that limit safety in clinical trials [55]. Opti-
mization of these in vitro culture methodologies is required.
In clinical trials, allogeneic whole tumor cells (melano-
ma, prostate, and pancreatic cancer), transduced with GM-
CSF,havebeenappliedclinicallyandshowntoinduceantitu-
mor immunity [67–69]. In this trial, whole allogeneic tumor
cells were genetically modiﬁed to secrete the immune stimu-
latory cytokine,GM-CSF, and then irradiated to prevent fur-
ther cell division. GM-CSF is now recognized to be the cru-
cialgrowthanddiﬀerentiationfactorforDCs.Therefore,this
approach is based on the concept that GM-CSF is required
a tt h es i t eo ft h et u m o rt oe ﬀectively prime TAAs-speciﬁc
immunity. Allogeneic GM-CSF-secreting pancreatic cancer
vaccine was conducted (Table 2). The vaccines induced
systemic antitumor immunity against autologous pancreatic
cancer cells [67]. The same group [70] administrated GM-
CSF-secreting allogeneic pancreatic cancer cells in sequence
withcyclophosphamideinpatientswithadvanced pancreatic
cancer. The approach showed minimal treatment-related
toxicity and mesothelin-speciﬁc T-cell responses. Moreover,
combination of the vaccine and cyclophosphamide resulted
in median survival in a gemcitabine-resistant population
similar to chemotherapy alone. It was also reported that
combination of the vaccines and chemoradiation demon-
strated an overall survival that compares favorably with
published data for resected pancreas cancer [69].
7.DC-Based Vaccines
DCs derive their potency from the prominent expression of
MHC class I and II, costimulatory (CD80 and CD86), and
adhesion molecules that provide secondary signals for the
activation of naive CD4+ and CD8+ T cells [24]. Therefore,Clinical and Developmental Immunology 7
Table 2: Whole tumor cell-based vaccines.
Patients Whole tumor cell-based
vaccines Combination Response Ref
14 resected
pancreatic cancer
Allogeneic
GM-CSF-secreting
pancreatic cancer cell
Vaccination induced increased
delayed-type hypersensitivity (DTH)
responses to autologous tumor cells in
three patients. [67]
3 patients also seemed to have had an
increased disease-free survival time,
remaining disease-free at least 25 months
after diagnosis.
30 advanced
pancreatic cancer
Allogeneic
GM-CSF-secreting
pancreatic cancer cell
Vaccine alone or in sequence
with cyclophosphamide
CD8+ T-cell responses to HLA class
I-restricted mesothelin epitopes were
identiﬁed predominantly in patients
treated with cyclophosphamide and
immunotherapy.
[70]
Cyclophosphamide-modulated
immunotherapy resulted in median
survival in a gemcitabine-resistant
population similar to chemotherapy
alone.
a major area of investigation in cancer immunotherapy in-
volves the design of DCs-based cancer vaccines [71, 72].
Several strategies to deliver TAAs including deﬁned or whole
antigens to DCs have been developed to generate a potent
CTL response against tumor cells in murine and human
systems (Figure 4). DCs have been pulsed with synthetic
peptide derived from the known tumor antigens [73], tumor
cell lysates [74], apoptotic tumor cells [75], or RMA derived
from tumor antigens [76] and transfected with whole tumor
cell DNA [77]o rR N A[ 78]. Moreover, DCs have been fused
with tumor cells to induce antigen-speciﬁc polyclonal CTL
responses [79]. In the DC/tumorcell fusion approach, whole
TAAs including those known and those yet unidentiﬁed are
processed endogenously and presented by MHC class I and
II pathways in the context of costimulatory signals [80–82].
Although DC-based vaccines have proven clinically safe and
eﬃcient to induce tumor-speciﬁc immune responses, only
a limited number of objective clinical responses have been
reported in cancer patients [83–86]. These relatively disap-
pointing results have prompted the evaluation of multiple
approaches to improve the eﬃcacy of DC-based vaccines.
DC-based vaccines have also been used for pancreatic
cancer (Table 3). The human tumor antigen mucin, encoded
by the gene MUC1, is a high-molecular-weight glycoprotein
that is overexpressed in adenocarcinomas including pancre-
atic cancer and hematological cancers and can be recog-
nized by cytotoxic T lymphocytes (CTLs) and monoclonal
antibodies [87]. A vaccine consisting of liposomal MUC1-
transfected autologous DCs was evaluated in a clinical phase
I/IItrial. InMUC1peptide-loadedDCvaccinesinpancreatic
and biliary cancer patients following resection of their pri-
mary tumors,4ofthe12patientsfollowed foroverfouryears
werealive,allwithoutevidenceofrecurrence[88].Moreover,
MUC1-speciﬁc immune responses were also observed even
in patients with pretreated and advanced disease, following
immunizationwithDCstransfected withMUC1cDNA[89].
As hTERT is the catalytic subunit of telomerase and a pro-
totype for a novel class of universal tumor antigens, it is one
of widely applicable targets recognized by CTLs [90]. In the
human system, DCs transfected with hTERT mRNA have
previously been shown to induce CTL responses to hTERT
in vitro [91].Furthermore, ﬁndings from initial clinicaltrials
demonstrate that hTERT-speciﬁc immune responses can be
safely induced in cancer patients [92]. A patient who could
not continue chemotherapy due to sever neutropenia had
been treated with autologous DCs transfected with hTERT
mRNA for 3 years and resulted in no evidence of active dis-
ease. Moreover, the complete remission (CR) was associated
with induction of hTERT-speciﬁc CD4+ and CD8+ T cells
[93].
8.DNA Vaccines
Cell-based cancer vaccines cause antitumor immune re-
sponse at ﬁrst. But they become less eﬀective over time be-
causetheinducedimmunesystemrecognizesthemasforeign
and quickly destroys them. DNA vaccines that consist of
TAAs and additional immune-stimulatory factors have an
advantage over cell-based vaccines because it can provide
prolonged antigen expression, leading to ampliﬁcation of
immune responses and inducing memory responses against
weakly immunogenic TAAs. Moreover, as DNA might be
taken up by cells and the encoded antigen is processed
through both endogenous and exogenous pathways, DNA
vaccines that administered via intramuscular injection allow
for an immune response to multiple potential epitopes with-
in an antigento begeneratedregardless of thepatient’sMHC
proﬁle [95]. DNA vaccines are now being studied in clinical
trialsformelanomaandprostatecancer.Inpancreaticcancer,
DNA vaccination targeting MUC1 [96] or survivin [97]h a s
been studied in murine models and resulted in antitumor
immune responses.8 Clinical and Developmental Immunology
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Figure 4: Strategies to deliver deﬁned or whole antigens to DCs. DCs used for cancer vaccines have been generated from the peripheral
blood monocytes of the patients using cytokines including GM-CSF and IL-4. To generate antigen-speciﬁc CTL response against tumor
cells, DCs have been loaded with deﬁned or whole tumor-associated antigens. For example, DCs loaded with synthetic peptide, antigenic
DNA, orRNA havebeen used. Moreover, whole tumor-associatedantigens includingdeﬁned andunidentiﬁed havebeen alsoloaded to DCs.
Table 3: DC-based vaccines.
Patients DC-based vaccines Response Ref
12 pancreatic and biliary
cancer patients with resected
tumors
MUC1 peptide-loaded DC 4 of the 12 patients followed for over four years
were alive.
[88]
10 patients with advanced
breast, pancreatic, or papillary
cancer
DC transfected with MUC1
cDNA
A vaccine-speciﬁc delayed-type
hypersensitivity (DTH) reaction was observed
in 3 out of 10 patients. [89]
4 patients showed a 2- to 10-fold increase in
the frequency ofMUC1-speciﬁc
IFN-gamma-secreting CD8+ T cells.
1 patient who could not
continue chemotherapy due
to sever neutropenia
DC transfected with hTERT
mRNA
The patient showed no evidence of active
disease based on PET/CT scans. [93]
The patient developed an immune response
against several hTERT-derived Th and CTL
epitopes.
49 patients with advanced
pancreatic cancer refractory to
standard chemotherapy
Peptide (WT1, MUC1, CEA,
and CA125)-loaded DC
2 patients showed complete remission (CR), 5
partial remission(PR) and 10 stable disease
(SD).
[94]
Gemcitabine/S-1 Median survival time was 360 days.
9.Chemotherapyand Immunotherapy
Recently, new paradigms have emerged in the ﬁeld of cancer
vaccine research. In particular, the potential use of combi-
nation therapies that incorporate immune modulators and
standard radio- and chemotherapy to synergize with cancer
vaccines has been discussed. Cytotoxic chemotherapy is gen-
erally considered immunosuppressive, because of its toxicity
for dividing cells in the bone marrow and peripheral lym-
phoid tissue. Therefore, the combination of cancer vaccines
with chemotherapies has been considered to be inappropri-
atebecausetheimmunosuppressiveeﬀectsofthechemother-
apy would negate the eﬃcacy of cancer vaccines. How-
ever, increasing evidences have been mounting to suggest
that immunotherapy has the possibility of achieving bet-
ter success when used in combination with conventionalClinical and Developmental Immunology 9
chemotherapy [98, 99]. A standard cytotoxic agent, gemc-
itabine, not only exerts direct antitumor activity, but also
mediatesimmunologicaleﬀectsrelevantforcancerimmuno-
therapy [100–102]. Cross-presentation of TAAs by DCs is
essentialforinductionofaugmentCTLresponses. Treatment
ofcancercells and DCswith gemcitabineresults inenhanced
cross-presentation of TAAs by DCs, CTL expansion, and
inﬁltration ofthetumor,all ofwhich areassociated withaug-
mented CTL [103–106]. The increase in cross-presentation
did not lead to tolerance [104, 105]. Moreover, gemcitabine
reduced the number of myeloid suppressor cells but did not
reduce CD4+ T cells, CD8+ T cells, NK cells, macrophages,
orBcells[107].Therefore,gemcitabinemaybenotimmuno-
suppressive and enhance responses to immunotherapy ad-
ministered to activate orsupport immune responses directed
toward driving eﬀector immunity to pancreatic cancer cells
[108]. Indeed, combination of DCs pulsed tumor cells with
gemcitabine augmented therapeutic eﬃcacy in vivo in a
murine pancreatic cancer model [109]. Moreover, Ramakr-
ishnan et al. [110] have reported that chemotherapeutic
agents caused upregulation of cation-independent mannose
6-phosphate receptor (CI-MPR) expression on cancer cells
and a concurrent increase in the uptake of granzyme B by
activated CTLsin a largenumberofneighboring cancercells.
As a result, CTLs may cause apoptosis in large numbers
of cancer cells manifesting in a clinically evident antitumor
eﬀect. Thus, such a combination therapy may be very pro-
mising approach to the treatment of patients with advanced
pancreatic cancers.
Tumors that developdrug resistance would still be a suit-
abletargetfor immunotherapy [111]. Ithasbeenwell known
thatthemajority ofpatientswith advanced pancreaticcancer
that respond initially to standard chemotherapies ultimately
undergo relapse due to the survival of small populations of
cells with cancer-initiating/cancer stem cell (CSC) fraction
[112]. These CSCs are a subpopulation of the tumor more
capable than other cells to self-propagate, initiate new
tumors diﬀerentiate into bulk tumor, and therefore sustain
tumor growth. Although chemotherapy kills most cancer
cells, it is believed to leave CSCs behind, which might be an
important mechanism of resistance [113]. CSCs are resistant
to a variety of treatments, including chemotherapy and
radiotherapy, with varied mechanisms of resistance, includ-
ing high expression of ATP-binding cassette (ABC) drug
transporters, an active DNA-repair capacity, and a resistance
to apoptosis [113, 114]. Recently, CSCs have been isolated
from various types of malignancies, including pancreatic
cancer [114–118]. According to the manner of expression in
CSCs, TAAs can be classiﬁed into two categories: (i) CSC-
speciﬁc antigens, such as SOX2 [119]a n dA L D H 1 A 1[ 120]
and (ii) shared antigens, such as CEP55 [121], MUC1 [122],
or WT1 [123, 124] between CSCs and more diﬀerentiated
subpopulations. Several methods to isolate CSC have been
reported, including cell surface markers such as CD44,
CD24, CD133, or epithelial-speciﬁc antigen (ESA) and
side population (SP) cells using Hoechst 33342 dye [115,
119, 120]. Puriﬁed tumor stem cells from a patient can be
used to immunize the patient or to activate the donor’s
immune cells against the tumor stem cells [113]. Therefore,
the developmentof strategies that target the CSC population
by immunotherapy may be highly desirable. Success of these
potential therapies will depend on how well immunological
responses to CSCs can be modulated by vaccines. We
recently generated hybrid cells by fusing DCs and CSCs to
activate potent CSC-speciﬁc CTL responses. The DC/CSC
fusions induced proliferation of T cells with high expression
levels of IFN-γ and enhanced killing of CSCs in vitro
[111]. Moreover, peptide-based cancer vaccines or adoptive
cell transfer of the CSC-speciﬁc CTL clone is a possible
approach for targeting chemotherapy-resistant CSCs [120].
These ﬁndings open a novel ﬁeld of investigations for future
clinical trial design, taking into account the immunostim-
ulatory capacity of chemotherapy such as gemcitabine, and
using them in combinedchemoimmunotherapy strategies in
patients with pancreatic cancer [103, 104, 106, 125, 126].
Moreover, it seems that a period of time exists between
the start of chemotherapy and immunotherapy. As the
fact that even without chemotherapy, antitumor immune
responses induced by immunotherapy cannot be sustained
for a long period of time in patients with cancer. It
would be important to establish the optimum timing and
schedulingofimmunotherapyandchemotherapy,toidentify
whether this synergistic eﬀect is limited to a speciﬁc type
of chemotherapy and whether immunotherapy can also
augment the clinical eﬀect of chemotherapy [44, 110, 127].
A combined approach of conventional therapies such as
radiation or chemotherapy kills the bulk of tumor cells, and
CSC-reactive CTL that target CSC fraction may represent a
more promising approach for the treatment of patients with
advanced pancreatic cancer (Figure 5).
In clinical trials, patients with advanced pancreatic can-
cer had been treated by combination therapy of standard
cytotoxic agent, gemcitabine with personalized peptides
[49, 128], or vascular endothelial growth factor receptor 2
(VEGFR2) [50]. The reactive personalized peptides (maxi-
mum of 4 kinds of peptides) were administered with gem-
citabine to patients with nonresectable pancreatic cancer.
Median survival time of all 21 patients was 9.0 months
with a one-year survival rate of 38%. Immune boosting
in both cellular and humoral responses was well correlated
with overall survival. Moreover, in combination therapy of
peptide for VEGFR2 with gemcitabine for patients with
metastatic and unresectable pancreatic cancer, the median
overall survival time of all 18 patients who completed at
least one course of the treatment was 8.7 months. VEGFR2-
speciﬁc CTL responses could be induced by the combination
therapy. The survival beneﬁt of combination therapy of
peptide vaccines and gemcitabine in comparison with gemc-
itabine alone needs to be conﬁrmed in randomized clinical
trials. Similar ﬁndings are also observed in combination
therapy of DCs-based cancer vaccines and gemcitabine.
Five patients with locally advanced pancreatic cancer had
been treated with gemcitabine, OK-432-stimulated DCs
injected into the tumor sites, and intravenous infusion
of lymphocyte-activated killer cells stimulated with anti-
CD3 monoclonal antibody [129]. In this report, 1 patient
had partial remission (PR) and 2 had long stable disease
(SD) more than 6 months. More recently, we also reported10 Clinical and Developmental Immunology
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Figure 5: Combination therapies of immunotherapy and standard radio- and chemotherapy. Currently applied standard therapies such as
radio- and chemotherapy target bulk cancer cells that are less resistant than cancer stem cells. This leads to initial regression of the tumor
mass but eventually regrowth from residual CSCs. Combined therapies of standard therapies and immunotherapeutic approach targeting
CSCs would cut oﬀ the rejuvenating supply of CSCs and resulted in tumor eradication.
that DC vaccine-based immunotherapies combined with
gemcitabine/S-1 were eﬀective in patients with advanced
pancreatic cancer refractory to standard chemotherapy [94].
As both WT1 and MUC1 are one of the excellent TAAs for
the target of immunotherapy and are frequently expressed in
pancreaticcancercells[36,37,123,130],38outof49patients
had receivedvaccinationwithWT1 peptide-pulsedDCswith
or without combination of other peptides such as MUC1,
CEA, and CA125 in this report. Prior to this combination
therapy, 46 out of 49 patients had been treated with
chemotherapy, radiotherapy, heavy particle radiotherapy, or
hyperthermia but elicited no signiﬁcant eﬀects. In spite of
these handicapped conditions, surprisingly, of 49 patients,
2 patients showed CR, 5 PR, and 10 SD, and median
survival time was 360 days. The use of DCs-based vaccines
in direct combination with chemotherapy in patients with
pancreatic cancer might become a veritable option for the
treatment of patients with advanced-stage cancer. Indeed,
gemcitabine enhanced WT1 expression in human pancreatic
cancer cells and sensitized the pancreatic cancer cells with
WT1-speciﬁc T cell-mediated antitumor responses [131].
Although the concept is far from being ﬁrmly established,
these reports may be suﬃcient to provide a platform for
the combination of immunotherapy with chemotherapy.
Evaluationiswarranted toexamine theeﬀectoftheapproach
on disease-free survival and overall survival.
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